The Centre for Digestive Diseases is internationally recognized for its expertise in gastrointestinal disorders and is a pioneer in the use of fecal microbiota transplantation (FMT). The introduction of the GA-map® Dysbiosis Test complements CDD's clinical focus on microbiome-related conditions, including irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), while providing clinicians with a standardized tool for assessing gut microbiota composition.

The GA-map® Dysbiosis Test is a clinically validated microbiome test designed to characterize deviations in the gut microbiota relative to a healthy reference population. By providing objective and reproducible insights into the microbial ecosystem, the test supports clinicians in the evaluation and management of patients with gastrointestinal disorders where the microbiome plays a significant role.

Ronny Hermansen, CEO of Genetic Analysis, comments: "The launch of the GA-map® Dysbiosis Test at the Centre for Digestive Diseases is an important achievement for Genetic Analysis and a major step in bringing our microbiome diagnostic technology to Australia. CDD is internationally recognized for its leadership in FMT and its extensive experience in treating patients with IBS and IBD. We believe this collaboration demonstrates the growing clinical interest in integrating microbiome-based diagnostics into patient care."

CDD has been at the forefront of microbiome-focused clinical practice for many years, making it a natural partner for the introduction of the GA-map® Dysbiosis Test in Australia. The implementation will provide healthcare professionals with access to actionable microbiome information that can support clinical decision-making and patient management.

Julie Simmons, Centre Manager at CDD, comments: "Understanding the gut microbiome is increasingly important in the management of gastrointestinal disorders. The addition of the GA-map® Dysbiosis Test aligns with our commitment to advancing microbiome-informed care and further strengthens our diagnostic capabilities for patients with microbiome-related conditions."

The Australian launch reinforces Genetic Analysis' commitment to expanding access to clinically validated microbiome diagnostics worldwide. As awareness of the microbiome's role in health and disease continues to grow, GA remains focused on providing healthcare professionals with reliable tools that help translate microbiome science into clinical practice.

For more information on Genetic Analysis, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

About Centre for Digestive Diseases

The Centre for Digestive Diseases (CDD), Sydney, Australia, is a specialist gastroenterology center recognized for its expertise in gastrointestinal disorders and microbiome-based therapies, including fecal microbiota transplantation (FMT). CDD provides advanced diagnostic and treatment solutions for patients with a wide range of digestive health conditions.

For more information, visit www.cdd.com.au

About Genetic Analysis AS

Genetic Analysis AS (GA) is a molecular diagnostics company focused on developing targeted microbiome-based solutions using its proprietary GA-map® platform. With more than 15 years of experience in microbiome research and product development, the company works across disease areas including IBS, IBD, and recurrent Clostridioides difficile infection. GA-map® enables standardized and reproducible profiling of clinically relevant microbial patterns, supporting both research and diagnostic applications. GA has a highly qualified team with expertise in molecular biology, bioinformatics, bioengineering, operations, and sales.

For more information, visit www.genetic-analysis.com

Interested in reading more about GA's products? Please visit ga-map.com

Stay updated on GA and sign up for more investor-related information:

https://www.genetic-analysis.com/subscriptions/